Identification of G0S2 as a gene frequently methylated in squamous lung cancer by combination of in silico and experimental approaches

International Journal of Cancer

Volumn 126, Issue 8, 2010, Pages 1895-1902

  Kusakabe, Masashi ^a   Kutomi, Tomoko ^a   Watanabe, Kousuke ^a   Emoto, Noriko ^a   Aki, Naomi ^a   Kage, Hidenori ^a   Hamáno, Emi ^a   Kitagawa, Hiroshi ^a   Nagase, Takahide ^a   Sano, Atsushi ^a   Yoshida, Yukihiro ^a   Fukami, Takeshi ^a   Murakawa, Tomohiro ^a   Nakajima, Jun ^a   Takamoto, Shinichi ^a   Ota, Satoshi ^a   Fukayama, Masashi ^a   Yatomi, Yutaka ^a   Ohishi, Nobuya ^a   Takai, Daiya ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Dna methylation; G0S2; Lung cancer; Real time pcr

Indexed keywords

BISULFITE; DNA; TUMOR MARKER; CELL CYCLE PROTEIN; G0S2 PROTEIN, HUMAN;

ALLELE; ARPC1B GENE; ARTICLE; BIOINFORMATICS; CANCER TISSUE; CHROMOSOME ABERRATION; COMPUTER MODEL; CONTROLLED STUDY; DNA EXTRACTION; DNA METHYLATION; DNAH9 GENE; FLRT2 GENE; FOLLOW UP; G0S2 GENE; GENE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; IRS2 GENE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; METHYLATION; MICROARRAY ANALYSIS; PKP1 GENE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RESTRICTION MAPPING; SPOCK1 GENE; UCHL1 GENE; CLUSTER ANALYSIS; DNA MICROARRAY; GENETIC EPIGENESIS; GENETICS; LUNG TUMOR;

CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CLUSTER ANALYSIS; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; LUNG NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77949877527     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24947     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer }Clin 2008;58:71-96,
2. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M., Lee JS, Mellemgaard A, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551
3. 3. Johnson DH, Fehrenbacher L, Novotný WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, III, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxei with carboplatin and paclitaxei alone in previously untreated locally advanced or metastatic non-smallcell lung cancer. ) Clin Oncol 2004;22: 2184-2191 (Pubitemid 41095154)
4. 4. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paciitaxel-carboplatin alone or with bevacizumab for non-smell-cell lung cancer, N Engl J Med 2006;355: 2542-2550 (Pubitemid 44917502)
5. 5. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349: 2042-2054 (Pubitemid 37448928)
6. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer, Nat Rev Genet 2002;3:415-428
7. 7. Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, Takamoto S, Murakami Y. Promoter methylation of the TSLCl gene in advanced lung tumors and various cancer cell lines. Int J Cancer 2003;107:53-59 (Pubitemid 37100085)
8. 8. Izumi H, Inoue J, Yokoi S, Hosoda H, Shibata T, Sunamori M, Hirohashi S, Inazawa J, Imoto I, Frequent silencing of DBCl is by genetic or epigenetic mechanisms in non-small cell lung cancers. Hum Mol Genet 2005;14:997-1007. (Pubitemid 40575875)
9. 9. Kim YT, Park SJ, Lee SH, Rang HJ, Hahn S, Kang CH, Sung SW, Kim JH. Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung. J Thorac Cardiovasc Surg 2005;130:1378. (Pubitemid 41543208)
10. 10. Safar AM, Spencer H, III, Su X, Coffey M, Cooney CA, Ratnasinghe LD, Hutchins LF, Fan CY. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system, Clin Cancer Res 2005; 11:4400-4405 (Pubitemid 40825630)
11. 11. Takal D, Yagi Y, Wakazono K, Ohishi N, Morita Y, Sugimura T, Ushijima T. Silencing of HTRlB and reduced expression of EDNl in human lung cancers, revealed by methylation-sensitive representational difference analysis. Oncogene 2001;20:7505-7513 (Pubitemid 33086910)
12. Virmani AK, Tsou JA, Siegmund KD, Shen LY, Long TI, Laird PW, Gazdar AF, LairdOffringa IA. Hierarchical clustering of lung cancer cell lines using DNA methylation markers. Cancer Epidemiol Biomarkers Prev 2002;11:291-297
13. 13. Wang J, Lee JJ, Wang L, Liu DD, Lu C, Fan YH, Hong WK, Mao L. Value of pl.6INK4a and RASSFlA promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res 2004;10:6119-6125 (Pubitemid 39287517)
14. 14. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glockner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky SA, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008; 358:1118-1128 (Pubitemid 351398486)
15. Sambrook J, Russell DW. Molecular cloning: a laboratory manual third edition, 3rd edn., vol.1. New York: Cold Spring Harbor Laboratory Press, 2001. 6.4-6.12
16. 16. Sano A, Kage H, Sugimoto K, Kitagawa H, Aki N, Goto A, Fukayama M, Nakajima J, Takamoto S, Nagase T, Yatomi Y, Ohishi N, et al. A second-generation profiling system for quantitative methylation analysis of multiple gene promoters: application to lung cancer. Oncogene 2007;26:6518-6525 (Pubitemid 47530604)
17. 17, Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay, Nucleic Acids Res 1997;25:2532-2534 (Pubitemid 27303718)
18. Zeschnigk M, Bohringer S, Price EA, Onadim Z, Masshofer L, Lohmann DR. A novel real-time PCR assay for quantitative analysis of methylated alleles (QAMA): analysis of the retinoblastoma locus. Nucleic Acids Res 2004;32:el25.
19. 19. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 2002;99:3740-3745 (Pubitemid 34252176)
20. Noro R, Gemma A, Miyanaga A, Kosaihira S, Minegishi Y, Nara M, Kokubo Y, Seike M, Kataoka K, Matsuda K, Okano T, Yoshimura A, et al. PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Oncol 2007;31:1157-1163
21. 21. Bonomi PD, Buckingham L, Coon J. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res 2007;13: S4606-1.2. (Pubitemid 47219733)
22. Metro G, Finocchiaro G, Toschi L, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino L, Cappuzzo F. Epidermal growth factor receptor (EGFR) targeted therapies in nonsmall cell lung cancer (NSCLC), Rev Recent Clin Trials 2006;1:1-13.
23. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004;4:988-993
24. 24. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:8681-8686 (Pubitemid 29354851)
25. Liu Z, Zhao J, Chen XF, Li W, Liu R, Lei Z, Liu X, Peng X, Xu K, Chen J, Liu H, Zhou QH, et al. CpG island methylator phenotype involving tumor suppressor genes located on. chromosome 3p in nonsmall cell lung cancer. Lung Cancer 2008; 62:15-22.
26. 26. Suzuki M, Shigematsu H, Iizasa T, Hiroshima K, Nakatani Y, Minna JD, Gazdar AF, Fujisawa T. Exclusive mutation in epidermal growth factor receptor gene. HER-2, and. KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer 2006;106:2200-2207, (Pubitemid 43673242)
27. Hayashi H, Nagae G, Tsutsumi S, Kaneshi.ro K, Kozaki T, Kaneda A, Sugisaki H, Aburatani H. High-resolution mapping of DNA methylation in human genome using oligonucleotide tiling array. Hum Genet 2007;120:701-711
28. 28, Rauch T, Wang Z, Zhang X, Zhong X, Wu X, Lau SK, Kernstine KH, Riggs AD, Pfeifer GP. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci USA 2007;104:5527-5532 (Pubitemid 47175714)
29. 29, Fukutomi S, Seki N, Koda K, Miyazaki M, Identification of methylation-silenced genes in colorectal cancer cell lines: genomic screening using oligonucleotide arrays. Scand J Gastroenterol 2007;42: 1486-1494 (Pubitemid 350125552)
30. 30, Kaneda A, Kaminishi M, Sugimura T, Ushijima T. Decreased expression of the seven ARP2/3 complex genes in human gastric cancers. Cancer Lett 2004;212: 203-210 (Pubitemid 38997976)
31. Tokumaru Y. Yamashita K, Osada M, Nomoto S, Sun DI, Xiao Y, Hoque MO, Westra WH, Califano JA, Sidransky D. Inverse correlation between cyclin Al hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res 2004;64: 5982-5987
32. 32, Yamashita S, Tsujino Y, Moriguchi K, Tatematsu M, Ushijima T. Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5aza-2'-deoxycytidine treatment and oligonucleotide microarray. Cancer Set 2006;97:64-71. (Pubitemid 43257029)
33. Yu J, Tao Q, Cheung KF, Jin H, Poon FF, Wang X, Li H, Cheng YY, Rocken C, Ebert MP, Chan AT, Sung JJ. Epigenetic identification of ubiquitin carboxylterminal hydrolase Ll as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology 2008;48: 508-518
34. 34, Welch MD, DePace AH, Verma S, Iwamatsu A, Mitchison TJ. The human Arp2/3 complex is composed of evoiutionarily conserved subunits and is localized to cellular regions of dynamic actin filament assembly. J Cell Biol 1997; 138:375-384 (Pubitemid 27323539)
35. 35, Vaughan KT, Mikami A, Paschal BM, Hoizbaur EL, Hughes SM, Echeverri CJ, Moore KJ, Gilbert DJ, Copeland NG, Jenkins NA, Vallée RB. Multiple mouse chromosomal loci for dynein-based motility. Genomics 1996;36: 29-38. (Pubitemid 26277755)
36. Lacy SE, Bonnemann CG, Buzney EA, Kunkel LM. Identification of FLRTl, FLRT2, and FLRT3: a novel family of transmembrane leucine-rich repeat proteins. Genomics 1999;62:417-426
37. Russell L, Forsdyke DR. A human putative lymphocyte G0/G1 switch gene containing a CpG-rich island encodes a small basic protein with the potential to be phosphorylated. DNA Cell Biol 1991;10: 581-591
38. 38. Bouzakri K, Zachrisson A, Al-Khalili L, Zhang BB, Koistinen HA, Krook A, Zierath JR. siRNA-based gene silencing reveals specialized roles of IRS-1/Akt2 and I.RS-2/ AkU in glucose and lipid metabolism in human skeletal muscle. Cell Metab 2006;4: 89-96. (Pubitemid 43964475)
39. 39. Hofmann I, Mertens C, Brettel M, Nimmrich V, Schnolzer M, Herrmann H. Interaction of plakophilins with desmoplakin and intermediate filament proteins: an in vitro analysis. J Set 2000;113 (Pt 13): 2471-2483 (Pubitemid 30601363)
40. AllielPM, Perin JP, Jolies P, Bonnet FJ. Testlcan, a multidomain testicular proteoglycan resembling modulators of cell social behaviour, Eur J Biochem 1993;214: 347-350
41. Larsen CN, Krantz BA, Wilkinson KD. Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry 1998;37:3358-3368
42. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sc USA 1996; 93:9821-9826
43. 43, de Maat MF, Umetani N, Sunami E, Turner RR, Hoon DS. Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles. Mol cancer Res 2007;5:461-471 (Pubitemid 46903955)
44. 44, Bestor TH. Unanswered questions about the role of promoter methylation in carcinogenesis. Ann NY Acad Sci 2003;983: 22-27 (Pubitemid 36399317)
45. Kantarjian H, Issa JP , Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Kiimek V, Slack J, de Castro C, Ravandi F, Helmer R, III, Shen L, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106: 1794-1803
46. 46, Duvic M, Taipur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-ceil lymphoma (CTCL). Blood 2007;109: 31-39 (Pubitemid 46053039)
47. Yoo CB, Chang JC, Byun H-M, Egger G, Yang AS, Dubeau L, Long T, Laird PW, Marquez VE, Jones PA. Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res 2008; 1: 233-240
48. 48, Toyooka S, Tokumo M, Shigematsu H, Matsuo K, Asano H, Tomii K, Ichihara S, Suzuki M, Aoe M, Date H, Gazdar AF, Shimizu N. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res 2006;66: 1371-1375 (Pubitemid 43259916)